ASAmit M. Saindane

Amit M. Saindane

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Amit M. Saindane has a total of 116 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Current State of Artificial Intelligence Adoption and Implementation in Neuroradiology Departments: Insights from a U.S. National Survey

    by Max Wintermark, Jason W. Allen, Rahul Bhala, Colin Derdeyn, Ajay Gupta, Christopher P. Hess, Joseph M. Hoxworth, Thierry Huisman, Mahesh V. Jayaraman, Ajay Malhotra, et al.

    Artificial intelligence (AI) is rapidly transforming medical imaging, yet its integration into neuroradiology remains uneven. This survey-based study assesses AI usage, tools, applications, barriers, and future expectations among U.S. neuroradiology departments. This cross-sectional survey questionnaire comprised 19 items, blending multiple-choice, multi-select, and open-ended formats. Descriptive statistics were used to identify patterns in data. Most departments (81%) reported AI use, primarily for stroke-related applications, with smaller numbers using tools for report generation, segmentation, and image quality enhancement. Most clinical tools were FDA-approved. AI had minimal perceived impact on workload, and performance was viewed as variable, with concerns about accuracy and false positives. Cost, integration challenges, and limited efficacy evidence were the main barriers to adoption. Despite these limitations, most respondents anticipated increased AI use over the next five years. Findings underscore the need for clinician-vendor collaboration to realize AI's potential in reducing workload and improving outcomes.


  • Two-Year Impact Following Transformation Into an Enterprise-Wide Imaging Modality-Based Radiology Management Structure

    by Amit M. Saindane, Laura Benson, Debra A. Smith, Linda Roesch, Kendra Moore, Susan Reich, Heather Dexter

  • Advancing safety culture through training: A just culture curriculum

    by N. Kadom, S. Reich, Z. Grunewald, L. Reynolds, A.M. Saindane, P. Balthazar

  • State of Practice: ASNR Statement on Gadolinium-Based Contrast Agent Use in Patients with Chronic Kidney Disease

    by Kirk M. Welker, David Joyner, Anthony W. Kam, David S. Liebeskind, Amit M. Saindane, Colin Segovis, Noushin Yahyavi-Firouz-Abadi, John E. Jordan

    Beginning in 2006, neuroradiologists became increasingly aware of the risk of nephrogenic system fibrosis (NSF) when patients suffering from chronic kidney disease (CKD) received gadolinium-based contrast agents (GBCAs) in conjunction with MRI scans. Radiology practices began withholding GBCAs from MRI patients with substantial CKD and instated a variety of safety measures to ensure that these individuals did not inadvertently receive GBCAs. As a result, the worldwide incidence of NSF was dramatically reduced. Since that time, a wealth of research on NSF and its etiology has found few unconfounded cases associated with those GBCAs categorized as Group II agents by the American College of Radiology. In 2023 and 2024, members of the American Society of Neuroradiology (ASNR) Standards and Guidelines Committee reviewed new research evidence on GBCA safety and its relevance to current MRI contrast administration guidelines for patients with CKD. This focused on systematic reviews and meta-analyses conducted during the past five years. Upon consideration of this literature, recommendations for administration of GBCAs to patients with CKD were formulated. For neuroimaging applications, the ASNR recommends that Group II GBCAs no longer be withheld in patients with CKD when these agents are medically indicated for diagnosis. Moreover, if Group II GBCAs are exclusively used in an MRI practice, other safety measures such as checking renal function or querying patients about chronic kidney disease can be discontinued. ACR = American College of Radiology; ASNR = American Society of Neuroradiology; CKD = chronic kidney disease; GBCA = gadolinium-based contrast agent; NSF = nephrogenic systemic fibrosis.


  • Cranial nerve abnormalities in spontaneous intracranial hypotension and their clinical relevance

    by Najdat Zohbi, Alexander Castilho, Sera Kim, Amit M. Saindane, Jason W. Allen, Michael J. Hoch, Brent D. Weinberg

    Background and Purpose: Spontaneous intracranial hypotension (SIH) is a known cause of headaches and neurologic symptoms, but the frequency of cranial nerve symptoms and abnormalities on magnetic resonance imaging (MRI) has not been well described. The purpose of this study was to document cranial nerve findings in patients with SIH and determine the relationship between imaging findings and clinical symptoms.Methods: Patients diagnosed with SIH with pre‐treatment brain MRI at a single institution from September 2014 to July 2017 were retrospectively reviewed to determine the frequency of clinically significant visual changes/diplopia (cranial nerves 3 and 6) and hearing changes/vertigo (cranial nerve 8). A blinded review of brain MRIs before and after treatment was conducted to assess for abnormal contrast enhancement of cranial nerves 3, 6, and 8. Imaging results were correlated with clinical symptoms.Results: Thirty SIH patients with pre‐treatment brain MRI were identified. Sixty‐six percent of patients had vision changes, diplopia, hearing changes, and/or vertigo. Cranial nerve 3 and/or 6 enhancement was present in nine patients on MRI, with 7/9 patients experiencing visual changes and/or diplopia (odds ratio [OR] 14.9, 95% confidence interval [CI] 2.2‐100.8, p = .006). Cranial nerve 8 enhancement was present in 20 patients on MRI, with 13/20 patients experiencing hearing changes and/or vertigo (OR 16.7, 95% CI 1.7‐160.6, p = .015).Conclusions: SIH patients with cranial nerve findings on MRI were more likely to have associated neurologic symptoms than those without imaging findings. Cranial nerve abnormalities on brain MRI should be reported in suspected SIH patients as they may support the diagnosis and explain patient symptoms.


  • Open Access

    Automated Registration and Color Labeling of Serial 3D Double Inversion Recovery MR Imaging for Detection of Lesion Progression in Multiple Sclerosis

    by Charlie C. Park, Marijn E. Brummer, Gelareh Sadigh, Amit M. Saindane, Mark E. Mullins, Jason W. Allen, Ranliang Hu

    Automated co-registration and subtraction techniques have been shown to be useful in the assessment of longitudinal changes in multiple sclerosis (MS) lesion burden, but the majority depend on T2-fluid-attenuated inversion recovery sequences. We aimed to investigate the use of a novel automated temporal color complement imaging (CCI) map overlapped on 3D double inversion recovery (DIR), and to assess its diagnostic performance for detecting disease progression in patients with multiple sclerosis (MS) as compared to standard review of serial 3D DIR images. We developed a fully automated system that co-registers and compares baseline to follow-up 3D DIR images and outputs a pseudo-color RGB map in which red pixels indicate increased intensity values in the follow-up image (i.e., progression; new/enlarging lesion), blue-green pixels represent decreased intensity values (i.e., disappearing/shrinking lesion), and gray-scale pixels reflect unchanged intensity values. Three neuroradiologists blinded to clinical information independently reviewed each patient using standard DIR images alone and using CCI maps based on DIR images at two separate exams. Seventy-six follow-up examinations from 60 consecutive MS patients who underwent standard 3 T MR brain MS protocol that included 3D DIR were included. Median cohort age was 38.5 years, with 46 women, 59 relapsing–remitting type MS, and median follow-up interval of 250 days (interquartile range: 196–394 days). Lesion progression was detected in 67.1% of cases using CCI review versus 22.4% using standard review, with a total of 182 new or enlarged lesions using CCI review versus 28 using standard review. There was a statistically significant difference between the two methods in the rate of all progressive lesions (P < 0.001, McNemar’s test) as well as cortical progressive lesions (P < 0.001). Automated CCI maps using co-registered serial 3D DIR, compared to standard review of 3D DIR alone, increased detection rate of MS lesion progression in patients undergoing clinical brain MRI exam.


  • Intracranial computed tomography histogram analysis detects changes in the setting of elevated intracranial pressure and normal imaging

    by Solmaz Asnafi, Benson S Chen, Valérie Biousse, Nancy J Newman, Amit M Saindane

    Background: Patients with idiopathic intracranial hypertension (IIH) have elevated intracranial pressure (ICP) of unclear etiology. This study evaluated the ability of quantitative intracranial Hounsfield unit (HU) histogram analysis to detect pathophysiological changes from elevated ICP in the setting of a normal head CT. Methods: Retrospective analysis of non-contrast-enhanced head CT images of IIH patients and matched controls. Following skull stripping, total intracranial CT voxels within the range of 0-70 HU were divided into seven 10 HU bins. A measurement of total intracranial HU was also calculated for each patient. Imaging studies for IIH patients were reviewed for features of IIH including transverse sinus stenosis (TSS). Histogram measures were compared between IIH and control groups and correlated with imaging and clinical data. Results: Fourteen IIH patients with CSF opening pressure ≥25 cm water, and 31 age-, sex-, and ethnicity-matched controls were included. Compared to controls, IIH patients had a significantly greater proportion of voxels in the 40-50, 50-60, and 60-70 HU bins ( p = 0.003, 0.001, and 0.003, respectively) but similar proportion in the 0-10 HU range. Severity of TSS significantly correlated with total intracranial HU measures. 50-60 HU and 60-70 HU bins demonstrated high AUCs of 0.81 and 0.80, respectively, in differentiating IIH from normal status. Conclusion: Idiopathic intracranial hypertension patients have a greater proportion of high intracranial HU voxels representing blood volume, which may be explained by TSS causing venous congestion. The pattern provides further insights into the pathophysiology of IIH and may be useful for detecting elevated ICP in the setting of normal head CT imaging.


  • Detection of Cortical and Deep Gray Matter Lesions in Multiple Sclerosis Using DIR and FLAIR at 3T

    by Charlie C. Park, Dean W. Thongkham, Gelareh Sadigh, Amit M. Saindane, Renxin Chu, Rohit Bakshi, Jason W. Allen, Ranliang Hu

    BACKGROUND AND PURPOSE: The comparative detection rates of deep gray matter (GM) multiple sclerosis (MS) lesions using double inversion recovery (DIR) and fluid‐attenuated inversion‐recovery (FLAIR) on 3T MR imaging remain unknown. We aimed to assess the detectability of cortical and deep GM MS lesions using DIR and FLAIR on 3T clinical exams and evaluate the relationship between deep GM lesions and brain atrophy.METHODS: One hundred fifty consecutive MS patients underwent routine brain MRI that included 3D DIR and 2D T2 FLAIR on the same 3T scanner. Three neuroradiologists independently reviewed all exams for cortical and deep GM lesions. Statistical parametric mapping (SPM) and FMRIB software library (FSL)‐FIRST pipelines were used to determine normalized whole brain and deep GM volumes.RESULTS: A total of 65 cortical and 98 deep lesions were detected on DIR versus 24 and 20, respectively, on FLAIR. Among all 150 patients, the number and percentage of patients with GM lesions on DIR and FLAIR were as follows: cortical 43 (28.7%) versus 24 (16.0%) (P < .001), thalamus 47 (31.3%) versus 20 (13.3%) (P < .001), putamen 10 (6.7%) versus 3 (2.0%) (P = .02), globus pallidus 9 (6.0%) versus 3 (1.3%) (P = .02), and caudate 5 (3.3%) versus 1 (0.7%) (P = .125). Presence of deep GM lesions weakly correlated with deep GM volume fractions.CONCLUSION: Deep GM MS lesions can be detected using routine clinical brain MRI including DIR and FLAIR at 3T. Future studies to optimize these sequences may improve the detection rates of cortical and deep GM lesions. The presence of GM lesions showed weak correlation with GM atrophy.